Physician profile
Nathan H Plunk
NPI 1700059268
$1,550.98
in general payments reported to CMS, 2019-2025
20 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $67.79 · 2021: $217 · 2022: $367 · 2023: $271 · 2024: $222 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $246.43 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.17 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $178.17 | 2019-2024 | |
| La Jolla Pharmaceutical Company | $169.08 | 2019-2023 | Xerava |
| Pfizer INC. | $153.60 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.26 | 2019-2024 | Jardiance |
| Abbvie INC. | $100.53 | 2023-2025 | |
| Tetraphase Pharmaceuticals, INC. | $41.59 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $40.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $39.03 | 2019-2021 | |
| Boston Scientific Corporation | $38.08 | 2023-2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $36.95 | 2022-2023 | Zerbaxa, Dificid |
| Abiomed | $29.40 | 2022 | |
| Stryker Corporation | $28.55 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Paratek Pharmaceuticals, INC. | $22.96 | 2025 | Nuzyra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19.36 | 2024 | Symplicity G3 |
| Novo Nordisk INC | $18.82 | 2023 | |
| Irhythm Technologies, INC. | $16.54 | 2019 | |
| Enterra Medical, INC. | $15.62 | 2023 | |
| Portola Pharmaceuticals, LLC | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Plunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.